CSE: BUX | OTCQB: BMKDF | FSE: 20B
BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for Early Lung Cancer Detection Largest Clinical Study Validating a Metabolite-based
Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright’s 26th Annual Global Investment conference in New York Vancouver, British Columbia – (August 26,
The U.S. Patent and Trademark Office Grants BIOMARK PATENT THAT EXPANDS ITS CLAIMS COVERING ITS LEGACY LIQUID BIOPSY ASSAY The new patent granted by the
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research At 2024 GPEN Conference Vancouver, British Columbia – (July 15, 2024) – BioMark Diagnostics Inc. (“BioMark” or
Today is a day to honour Dr Daniel Sitar: Fellowship Canadian Society of Pharmacology and Therapeutics Daniel Sitar BScPharm, MSc, PhD, FGSA,FCP, Professor Emeritus, Rady
Scottland’s NHS has raised concerns about the future of its NHS breast cancer screening program.
BIOMARK Announces Warrant Extension and Granting of Options Vancouver, British Columbia – (April 18th, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX)
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study.
Vancouver, British Columbia – (February 28, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid
